At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...
Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...
Montreal, July 13, 2026 – Novartis Pharmaceuticals Canada Inc. (“Novartis Canada”) announced today that Health Canada has granted approval for VANRAFIA TM (atrasentan tablets) for proteinuria ...
. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...
If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in Europe Scemblix ...
New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase III ...
Behind every transformational leader is a remarkable story. For Reshema Kemps-Polanco, Chief Commercial Officer of Novartis US, it's a journey that weaves together military discipline, a sharp ...
Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42. Although artificial intelligence has been ...
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo ...
. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
. Novartis is providing the information in this press release as of this date and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release as ...
Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results